Skip to content

Cagrilintide: Side Effects & Safety

Part of the Cagrilintide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Overall Safety Profile

Cagrilintide's safety profile in clinical trials is similar to other incretin-based therapies, with gastrointestinal effects being most common. Safety data is still accumulating as Phase 3 trials are ongoing.

Reported Side Effects

  • Nausea: Most common, generally mild to moderate, decreasing over time
  • Vomiting and diarrhea: Common GI effects
  • Injection site reactions: Mild and transient
  • Decreased appetite: Therapeutic effect but can be excessive

Important Limitations

Cagrilintide is still in Phase 3 clinical trials. Long-term safety data (>1 year) is limited. The effects of chronic amylin receptor activation on bone density, pancreatic function, and other organ systems require further characterization.

Potential Contraindications

  • Known hypersensitivity to amylin analogs
  • Gastroparesis or severe GI motility disorders
  • Pregnancy and breastfeeding (no safety data)

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.